Munk Dialogue with Paul Offit

October 21, 2022
00:00:00
00:00:00

Munk Dialogue with Paul Offit

The Bivalent COVID-19 Booster: do the benefits outweigh the risks?

Health Canada, the FDA, and the CDC have approved COVID bivalent vaccines to anyone over the age of 12. This booster is different from previous COVID shots, targeting multiple strains of the novel coronavirus, including Omicron sub variants. And while the vaccine is being widely distributed, some epidemiologists are sounding the alarm.

Dr. Paul Offit, Director of the Vaccine Education Center and attending physician in the Division of Infectious Diseases at Children’s Hospital of Philadelphia, is one of two members on the FDA committee who voted against advising all adults over the age of 12 to get the jab. Offit joins Rudyard Griffiths for a talk about the Bivalent COVID-19 boosters, who should be getting them, and where more study is warranted.

“The data that we were shown didn’t make it clear that the bivalent vaccine was any better…boosters are a value, but I don’t see why the bivalent one is better than what we have already been getting.”

– PAUL OFFIT

Share
00:00:00
00:00:00